OCV C02

Drug Profile

OCV C02

Alternative Names: OCV-103/104; OCV-103/OCV-104; OCV-104/103; OCV-104/OCV-103; OCV-C02

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Otsuka Pharmaceutical
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 12 Jan 2015 Phase-I development is ongoing in Japan
  • 01 Mar 2013 Phase-I clinical trials in Colorectal cancer (second-line therapy or greater, late-stage disease) in Japan (Parenteral)
  • 31 Dec 2003 Preclinical trials in Colorectal cancer in Japan (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top